Value-based care got operationalized on the third try.
The phrase value-based care has had three meanings in U.S. healthcare since 2018, and the third one is the one that actually got operationalized.
The 2018 meaning was capitation-class risk-bearing. Providers (or provider-aligned entities) would take on full or partial financial risk for the total cost of care for a defined patient population, with shared savings or shared losses against a benchmark. The CMS Innovation Center models, the various Medicare ACO programs, the early commercial-payer pilots all sat in this register. The 2018 trade-press story was that value-based care meant providers becoming small insurance companies, with the operational implication that the providers needed actuarial-and-population-health capability they mostly did not have. The pilots that ran in this register produced uneven results and the operator class running them learned, expensively, that being a small insurance company is harder than the consultancy-class made it look.
The 2022 meaning had migrated to bundled-payment-and-episode-based-care. Specific procedures or specific episode types (joint replacement, maternity, cancer-treatment-courses) would be priced as bundles, with the providing entity managing the unit-cost of the bundle and capturing margin from efficiency improvements. This was a narrower scope than the 2018 meaning and produced more reliable operational results. The trade-press story shifted accordingly. The 2022 meaning was less ambitious, more deployable, and substantially more boring than the 2018 meaning, which is why the trade press wrote about it less.
The 2026 meaning, the one that has actually shipped at scale and is the most operationally useful, is sub-population-specific risk-and-quality contracts run through the Medicare Advantage and Medicaid Managed Care infrastructure. Health-system-aligned medical groups take partial risk for specific Medicare Advantage population slices (the chronic-condition cohorts, the dual-eligible cohorts, the high-utilizer cohorts) under contracts where the unit economics are sized to the provider's actual operational capacity. The 2026 meaning is narrower than the 2018 ambition, more diffuse than the 2022 bundled-payment scope, and substantially more sustainable than either. It is also so unexciting that the trade press has been generally not running the story.
The structural reason the third version is the one that shipped is that it is the version sized to the operational reality of what U.S. health systems can actually do. The 2018 vision required actuarial-and-population-health capability the providers did not have and could not acquire quickly. The 2022 vision required care-pathway-management capability that worked for selected episode types and did not generalize. The 2026 version requires that the provider can manage one specific population sub-segment under one specific contract structure, which is in the operational range of most large medical groups and large health systems.
The 2026 meaning is also the one that produces durable financial results. The shared-savings and partial-risk dollars run through it are smaller per-contract than the 2018 vision implied, but the contracts ship at scale, the operational mechanics work, and the program-level economics for both the provider and the payer are sustainable in a way the 2018 and 2022 versions struggled with.
For the operator class building healthcare products that interface with value-based care, the practical advice is to build for the 2026 meaning, not the 2018 ambition. The buyer is the Medicare Advantage and Medicaid Managed Care provider organizations running sub-population contracts. The product needs to support that workflow. The vendors still pitching against the 2018 vision are pitching against a market that has moved on without them.
Value-based care got operationalized on the third try. The third try is the version that lives. The trade press will eventually catch up to that. The operator class already has.
—TJ